Logo-bi
Perspective
Mohammad A. Rafi, Yadollah Omidi* ORCID
Bioimpacts. 2015;5(3): 117-122. doi: 10.15171/bi.2015.22
PMCID: PMC4597158     PMID: 26457248     Scopus ID: 84944384880    
PDF
XML
Cited By:
Original Research
Francesco Angelini*, Vittoria Ionta, Fabrizio Rossi, Fabio Miraldi, Elisa Messina, Alessandro Giacomello
Bioimpacts. 2016;6(1): 15-24. doi: 10.15171/bi.2016.03
PMCID: PMC4916547     PMID: 27340620     Scopus ID: 84977134342    
Original Research
Nasrollah Jabbari ORCID, Maryam Feghhi, Omid Esnaashari, Hamid Soraya, Jafar Rezaie* ORCID
BioImpacts. 2022;12(6): 549-559. doi: 10.34172/bi.2022.23489
PMCID: PMC9809134     PMID: 36644548     Scopus ID: 85143387474    
Treatment of MCF-10a, MCF-7, and MDA-MD-231 cells with Gallic acid resulted in inhibition in the activity of the exosomal secretory pathway. Gallic acid can decrease the expression of genes involved in exosomes biogenesis (Alix and CD63) and secretion (Rab proteins). In addition, Gallic acid can change the expression of autophagy markers (LC3 and P62) in these cells. MVB: multivesicular body.
Original Article
Nahid Moradi ORCID, Saeid Kaviani* ORCID, Mina Soufizomorrod* ORCID, Simzar Hosseinzadeh* ORCID, Masoud Soleimani ORCID
Bioimpacts. 2023;13(5): 425-438. doi: 10.34172/bi.2022.24142
PMCID: PMC10509736     PMID: 37736343     Scopus ID: 85172768741    
Editorial
Yalda Rahbar Saadat ORCID, Jaleh Barar* ORCID
BioImpacts. 2022;12(2): 87-88. doi: 10.34172/bi.2022.24253
PMCID: PMC8905586     PMID: 35411296     Scopus ID: 85127210127    
Jaleh Barar (PharmD, Ph.D.) is a Full Professor at the Faculty of Pharmacy, Tabriz University of Medical Sciences. Professor Barar is working on various aspects of pharmaceutical cell biology with particular emphasis on the development of novel drug delivery/targeting systems. Dr Barar is listed among top 1% of world scientists based on ESI ranking system.
Original Article
Yuri Yu. Shchegolev ORCID, Danila V. Sorokin, Alexander M. Scherbakov* ORCID, Olga E. Andreeva ORCID, Diana I. Salnikova ORCID, Ekaterina I. Mikhaevich ORCID, Margarita V. Gudkova ORCID, Mikhail A. Krasil’nikov ORCID
Bioimpacts. 2023;13(4): 313-321. doi: 10.34172/bi.2023.27490
PMCID: PMC10460766     PMID: 37645026     Scopus ID: 85168127787    
Prolonged cell treatment with mTOR inhibitor rapamycin leads to the development of resistance. Exosomes of resistant cells induce the resistance to rapamycin in the parent MCF-7cells. Exosome-induced resistance reproduces the changes revealed in the rapamycin-resistant cells, including the activation of ERK/AP-1.
Original Article
Nahid Moradi ORCID, Mina Soufi-Zomorrod* ORCID, Simzar Hosseinzadeh, Masoud Soleimani
Bioimpacts. 2024;14(3): 27510. doi: 10.34172/bi.2023.27510
PMCID: PMC11199929     PMID: 38938758     Scopus ID: 85194772548    
PDF
XML
Cited By:
Review
Naeimeh Akbari-Gharalari ORCID, Sina Khodakarimi, Farshad Nezhadshahmohammad, Mohammad Karimipour, Abbas Ebrahimi-Kalan* ORCID, Jiagian Wu
Bioimpacts. 2024;14(5): 30153. doi: 10.34172/bi.2023.30153
PMCID: PMC11406431     PMID: 39296798     Scopus ID: 85209251111    
PDF
XML
Cited By:


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge